HopeStage
Back to all studies
CompletedNCT06429722

NMRA-335140 for depression symptoms in bipolarity type II

About this title

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Read the official source — NCT06429722

Researchers compared NMRA-335140 80 mg and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared NMRA-335140 80 mg and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who was this study for?

This study was for people with type II bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Phoenix and 20 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 13, 2024
Recruitment status
Completed
Enrollment listed in the registry
18
Sponsor
Neumora Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06429722
Official title
Show the full official title

A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix · Little Rock · Garden Grove

18 more locations
  • Long Beach
  • San Jose
  • Torrance
  • Gainesville
  • Lauderhill
  • Maitland
  • Miami
  • Miami Lakes
  • Marietta
  • Savannah
  • Watertown
  • Flowood
  • Marlton
  • Princeton
  • Toms River
  • Brooklyn
  • Houston
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared NMRA-335140 80 mg and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who is behind this study?

The study sponsor is Neumora Therapeutics, Inc.

Did this study involve medication?

Yes. The study involved medication, including NMRA-335140 80 mg and Placebo.

Who was this study for?

This study was for people with type II bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies